Tylenol maker rebounds a day after unfounded claims about its safety
By Michelle Chapman
Extra Strength Tylenol is shown in Carmel, Ind., Tuesday, Sept. 23, 2025. (AP Photo/Michael Conroy)
Shares of Tylenol maker Kenvue bounced back sharply at the opening bell Tuesday, a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism.
“Don’t take Tylenol,” Trump instructed pregnant women around a dozen times during the White House news conference Monday, also urging mothers not to give their infants the drug, known by the generic name acetaminophen in the U.S. or paracetamol in most other countries.
Shares of the New Jersey consumer brands company tumbled 7.5% Monday. At the open of trading, shares bounced back by more than 6%.
The announcement, which appeared to rely on existing studies rather than significant new research, arrives as Health and Human Services Secretary Robert F. Kennedy Jr., a vaccine skeptic, advances the Make America Healthy Again movement that has focused on what it sees as potential causes of autism.
Kenvue disputed any link between the drug and autism this week and warned that if pregnant mothers don’t use Tylenol when in need, they could face a dangerous choice between suffering fevers or using riskier alternatives.
Kenvue was spun off from Johnson & Johnson’s pharmaceutical and medical device divisions in 2023 because it was thought that the companies could function more efficiently if they were independent from each other. Aside from Tylenol, the consumer health company makes Band-Aids, Listerine and other household brand names.
Citi Investment Research analyst Filippo Falorni wrote that he sees a limited risk of new lawsuits after Trump’s announcement, but thinks “there could be risk to Tylenol consumption given the negative headlines.”
Falorni anticipates a positive reaction for Kenvue’s stock at the opening bell on Tuesday given the lack of new scientific evidence.
The company has fought hundreds of lawsuits related to the product and its alleged ties to autism, but most have been dismissed.
Tylenol made headlines in the 1980s when seven people in the Chicago area were killed after taking the over-the-counter painkiller laced with cyanide. The incident triggered a nationwide panic and led to an overhaul in the safety of over-the-counter medication packaging. No one was ever charged in the deaths.
U.S. sports betting is booming as NFL and college football fuel massive activity. BetMGM CEO Adam Greenblatt breaks down trends, growth, and what’s next.
President Donald Trump says a deal struck by Netflix last week to buy Warner Bros. Discovery “could be a problem” because of the size of the combined market share. The Republican president says he will be involved in the decision about whether federal regulators should approve the deal. Trump commented Sunday when he was asked about the deal as he walked the red carpet at the Kennedy Center Honors. The $72 billion deal would bring together two of the biggest players in television and film and potentially reshape the entertainment industry.
Disney's changes to a program for disabled visitors are facing challenges in federal court and through a shareholder proposal. The Disability Access Service program, which allows disabled visitors to skip long lines, was overhauled last year. Disney now mostly limits the program to those with developmental disabilities like autism who have difficulty waiting in lines. The changes have sparked criticism from some disability advocates. A shareholder proposal submitted by disability advocates calls for an independent review of Disney's disability policies. Disney plans to block this proposal, claiming it's misleading. It's the latest struggle by Disney to accommodate disabled visitors while stopping past abuses by some theme park guests.
With a merger this big, creators, studios, and theaters all face uncertain futures. Here’s what experts are worried about and what good could come from it.
With disengagement rising and hybrid work shifting, 'Everybody Matters' author Bob Chapman explains why treating people well could define the future of work.
We sat down with Ali Furman, U.S. Consumer Markets Industry Leader at consulting firm PwC to ask what trends she garnered from the initial data this year.
Seth Schachner breaks down Zootopia 2’s record-smashing debut, holiday box office trends, early 2026 Oscar contenders, and what’s next for Netflix and WBD.
